These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628 [TBL] [Abstract][Full Text] [Related]
3. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Kiguchi K; Ruffino L; Kawamoto T; Ajiki T; Digiovanni J Clin Cancer Res; 2005 Aug; 11(15):5572-80. PubMed ID: 16061875 [TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
5. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. Xian W; Rosenberg MP; DiGiovanni J Oncogene; 1997 Mar; 14(12):1435-44. PubMed ID: 9136987 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020 [TBL] [Abstract][Full Text] [Related]
7. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Zheng Y; Izumi K; Yao JL; Miyamoto H Endocr Relat Cancer; 2011 Aug; 18(4):451-64. PubMed ID: 21613411 [TBL] [Abstract][Full Text] [Related]
8. Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Cheng K; Raufman JP Biochem Pharmacol; 2005 Oct; 70(7):1035-47. PubMed ID: 16139803 [TBL] [Abstract][Full Text] [Related]
9. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. Kitamura T; Connolly K; Ruffino L; Ajiki T; Lueckgen A; DiGiovanni J; Kiguchi K J Hepatol; 2012 Jul; 57(1):84-91. PubMed ID: 22326466 [TBL] [Abstract][Full Text] [Related]
10. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598 [TBL] [Abstract][Full Text] [Related]
11. Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Kiesslich T; Alinger B; Wolkersdörfer GW; Ocker M; Neureiter D; Berr F Int J Oncol; 2010 Jan; 36(1):49-58. PubMed ID: 19956832 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of growth factors and their receptors as potential therapeutic targets for biliary tract carcinoma. Ojima H J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):319-25. PubMed ID: 22278347 [TBL] [Abstract][Full Text] [Related]
13. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946 [TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172 [TBL] [Abstract][Full Text] [Related]
16. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. Kawamoto T; Ishige K; Thomas M; Yamashita-Kashima Y; Shu S; Ishikura N; Ariizumi S; Yamamoto M; Kurosaki K; Shoda J J Gastroenterol; 2015 Apr; 50(4):467-79. PubMed ID: 25112701 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050 [TBL] [Abstract][Full Text] [Related]
18. Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol. Miyagawa S; Katsu Y; Watanabe H; Iguchi T Oncogene; 2004 Jan; 23(2):340-9. PubMed ID: 14647453 [TBL] [Abstract][Full Text] [Related]
19. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Yoon SO; Shin S; Lipscomb EA Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594 [TBL] [Abstract][Full Text] [Related]
20. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]